O'Connor Padraig Andrew 4

What Happened

• Padraig Andrew O'Connor, EVP, Global Operations of Boston Scientific (BSX), had 1,802 restricted stock units (RSUs) convert to common shares on May 2, 2026. The RSUs converted at a $0 exercise price (i.e., no cash paid).
• To satisfy tax withholding, 872 of the newly issued shares were withheld/disposed at $56.50 per share, totaling $49,268. The net issuance/ownership change after withholding is not specified in the provided excerpt.

Key Details

• Transaction date: May 2, 2026; Form filed May 4, 2026 (timely).
• Reported transactions: conversion/exercise of derivative (code M) for 1,802 shares (acquired) and a related derivative entry; tax withholding (code F) of 872 shares at $56.50/share = $49,268.
• Footnotes: F1 — each RSU equals one share on settlement; F2 — these RSUs are paid in four equal annual installments starting May 2, 2023 (this grant vests in installments).
• No cash purchase or open-market sale by the insider—this was a routine RSU settlement and tax withholding, not an indication of a buy or sell decision.

Context

• This was an RSU settlement (derivative conversion), not a market purchase or voluntary sale. Withholding of shares to cover taxes is common and typically administrative rather than a signal of insider sentiment.
• The filing shows both the conversion of the RSUs and the withholding event; together they reflect the vesting/settlement process for the grant.